Johnson & Johnson reported first quarter of 2026 earnings that beat analysts’ estimates, prompting a raised full‑year outlook.
The beat gives investors confidence in JNJ’s pipeline and supports a higher earnings forecast for the rest of the year, which could lift the stock’s valuation as analysts upgrade their models. Citi and other brokerages have already nudged price targets upward in response to the results[2].
Revenue topped $22 billion, exceeding the consensus estimate of $21.5 billion, and earnings per share came in at $2.73, above the $2.65 forecast. The company attributed the outperformance to strong oncology and immunology sales, while noting that operating margins improved modestly thanks to disciplined cost control[2].
Darzalex, JNJ’s multiple‑myeloma therapy, recorded roughly $4 billion in sales this quarter, while its psoriasis drug Tremfya added about $1.6 billion, offsetting a steep drop in Stelara revenue. The two products together contributed more than half of the quarter’s total pharmaceutical revenue[1]. >Darzalex generated roughly $4 billion in sales this quarter.
Stelara, the company’s blockbuster for inflammatory bowel disease, saw sales fall sharply year‑over‑year, a trend analysts said could pressure future growth if not mitigated. The decline was largely attributed to increased competition and pricing pressures in the biologics market.
Citi analysts lifted their price target on JNJ to $285 from $274, citing the earnings beat and durable drug franchise. The stock also benefits from a 63‑year dividend streak, the longest among S&P 500 firms, reinforcing its appeal to income‑focused investors[3][4]. >Citi lifted its price target on JNJ to $285.
Market strategists estimate the stock could rally as much as 20% in the weeks after the report, based on the earnings surprise and upgraded guidance. The potential gain reflects both the strength of the drug pipeline and the broader market’s appetite for defensive health‑care stocks[5]. >Analysts see a potential 20% post‑earnings stock gain.
Following the release, JNJ shares rose about 3% in pre‑market trading and have been trending higher on the news, with several brokerages maintaining a buy rating. The consensus view is that the company’s diversified portfolio and steady dividend payout position it well for continued performance throughout 2026.
“Darzalex generated roughly $4 billion in sales this quarter.”
The earnings beat shows that Johnson & Johnson’s core pharmaceuticals are offsetting weakness in older products, giving the company a stronger earnings runway for 2026. Higher price targets and a long dividend streak make the stock attractive to both growth and income investors, while the potential 20% upside signals that the market may still be underpricing the company’s future cash‑flow generation.
